264 related articles for article (PubMed ID: 27701176)
1. The Protective Effect of Febuxostat on Chronic Tacrolimus-Induced Nephrotoxicity in Rats.
Kim HS; Lim SW; Jin L; Jin J; Chung BH; Yang CW
Nephron; 2017; 135(1):61-71. PubMed ID: 27701176
[TBL] [Abstract][Full Text] [Related]
2. Cilastatin protects against tacrolimus-induced nephrotoxicity via anti-oxidative and anti-apoptotic properties.
Luo K; Lim SW; Jin J; Jin L; Gil HW; Im DS; Hwang HS; Yang CW
BMC Nephrol; 2019 Jun; 20(1):221. PubMed ID: 31200653
[TBL] [Abstract][Full Text] [Related]
3. Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model.
Lee HJ; Jeong KH; Kim YG; Moon JY; Lee SH; Ihm CG; Sung JY; Lee TW
Am J Nephrol; 2014; 40(1):56-63. PubMed ID: 25034030
[TBL] [Abstract][Full Text] [Related]
4. Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia.
Omizo H; Tamura Y; Morimoto C; Ueno M; Hayama Y; Kuribayashi-Okuma E; Uchida S; Shibata S
Sci Rep; 2020 Jun; 10(1):9326. PubMed ID: 32518351
[TBL] [Abstract][Full Text] [Related]
5. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia.
Sánchez-Lozada LG; Tapia E; Soto V; Avila-Casado C; Franco M; Wessale JL; Zhao L; Johnson RJ
Nephron Physiol; 2008; 108(4):p69-78. PubMed ID: 18434753
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.
Sofue T; Inui M; Hara T; Nishijima Y; Moriwaki K; Hayashida Y; Ueda N; Nishiyama A; Kakehi Y; Kohno M
Drug Des Devel Ther; 2014; 8():245-53. PubMed ID: 24600205
[TBL] [Abstract][Full Text] [Related]
7. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress.
Tsuda H; Kawada N; Kaimori JY; Kitamura H; Moriyama T; Rakugi H; Takahara S; Isaka Y
Biochem Biophys Res Commun; 2012 Oct; 427(2):266-72. PubMed ID: 22995295
[TBL] [Abstract][Full Text] [Related]
8. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.
Sánchez-Lozada LG; Tapia E; Soto V; Avila-Casado C; Franco M; Zhao L; Johnson RJ
Nephrol Dial Transplant; 2008 Apr; 23(4):1179-85. PubMed ID: 18048425
[TBL] [Abstract][Full Text] [Related]
9. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
[TBL] [Abstract][Full Text] [Related]
10. Time to target uric acid to retard CKD progression.
Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
[TBL] [Abstract][Full Text] [Related]
11. Green tea polyphenols decreases uric acid level through xanthine oxidase and renal urate transporters in hyperuricemic mice.
Chen G; Tan ML; Li KK; Leung PC; Ko CH
J Ethnopharmacol; 2015 Dec; 175():14-20. PubMed ID: 26344851
[TBL] [Abstract][Full Text] [Related]
12. The molecular insight into the antihyperuricemic and renoprotective effect of Shuang Qi gout capsule in mice.
Kodithuwakku ND; Feng YD; Zhang YY; Pan M; Fang WR; Li YM
J Ethnopharmacol; 2015 Apr; 163():278-89. PubMed ID: 25614106
[TBL] [Abstract][Full Text] [Related]
13. Effects of Febuxostat on Oxidative Stress.
Fukui T; Maruyama M; Yamauchi K; Yoshitaka S; Yasuda T; Abe Y
Clin Ther; 2015 Jul; 37(7):1396-401. PubMed ID: 25913922
[TBL] [Abstract][Full Text] [Related]
14. Mangiferin Inhibits Renal Urate Reabsorption by Modulating Urate Transporters in Experimental Hyperuricemia.
Yang H; Gao L; Niu Y; Zhou Y; Lin H; Jiang J; Kong X; Liu X; Li L
Biol Pharm Bull; 2015; 38(10):1591-8. PubMed ID: 26228630
[TBL] [Abstract][Full Text] [Related]
15. Linagliptin ameliorates tacrolimus-induced renal injury: role of Nrf2/HO-1 and HIF-1α/CTGF/PAI-1.
Nady ME; El-Raouf OMA; El-Sayed EM
Mol Biol Rep; 2024 May; 51(1):608. PubMed ID: 38704766
[TBL] [Abstract][Full Text] [Related]
16. Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
Uchida S; Kumagai T; Chang WX; Tamura Y; Shibata S
Contrib Nephrol; 2018; 192():56-68. PubMed ID: 29393121
[TBL] [Abstract][Full Text] [Related]
17. [Effect of total saponin of Dioscorea on chronic hyperuricemia and expression of URAT1 in rats].
Chen GL; Zhu LR; Na S; Li L
Zhongguo Zhong Yao Za Zhi; 2013 Jul; 38(14):2348-53. PubMed ID: 24199570
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions.
Piao SG; Lim SW; Doh KC; Jin L; Heo SB; Zheng YF; Bae SK; Chung BH; Li C; Yang CW
Transplantation; 2014 Jul; 98(1):22-8. PubMed ID: 24825522
[TBL] [Abstract][Full Text] [Related]
19. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
[TBL] [Abstract][Full Text] [Related]
20. Ameliorative effects of sildenafil and/or febuxostat on doxorubicin-induced nephrotoxicity in rats.
Khames A; Khalaf MM; Gad AM; Abd El-Raouf OM
Eur J Pharmacol; 2017 Jun; 805():118-124. PubMed ID: 28257823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
